title: Enhanced antitumor effect of combination intravesical mitomycin C and bacillus Calmette-Guerin therapy in an orthotopic bladder cancer model.
abstract: Intravesical immunotherapy with bacillus Calmette-Guerin (BCG) is currently the most successful adjuvant agent for the treatment and/or prophylaxis of non-muscle-invasive bladder cancer (NMIBC). However, NMIBCs recur in 60-70% of cases and 30% of these recurrent tumors present with a higher grade and more invasive properties. Patients that do not respond to intravesical BCG therapy are considered to be a challenge for urologists. Thus, novel conservative possibilities should be explored. To test the efficacy of a novel therapeutic approach, we examined the antitumor effect of combination therapy by intravesical administration of mitomycin C (MMC) plus BCG, infusing the two drugs simultaneously, in an orthotopic bladder cancer model. Intravesical BCG and MMC administration showed a dose-dependent survival (n=8 per group). The combination of MMC and BCG provided a significant survival advantage compared to the BCG-alone (p=0.035) and MMC-alone groups (p=0.040) (n=8 per group). The group with combined MMC/BCG exhibited a survival period similar to that achieved with an amount eight times higher that of BCG (n=10 per group). Ki-67 labeling index of cancer cells, showing tumor proliferation, was significantly lower in the combined group compared to the BCG-alone (p<0.05), MMC-alone (p<0.01) and control groups (p<0.01). No difference was detected between the combined group and the BCG-alone group with regard to CD3, T-cell infiltration and CD68 macrophage activity. The combined MMC/BCG treatment decreased the tumor appearance rate, improved the survival period and reduced the cellular proliferation rate in tumors compared to the BCG-alone treatment. The results suggest that the combined intravesical MMC/BCG treatment induced an enhanced antitumor effect against bladder tumors. The combined MMC/BCG treatment also showed a survival period similar to that achieved using a dose eight times higher of BCG-alone.
authors.affiliation: Department of Urology, Saitama Medical School, Saitama 350-0495.
authors.forename: Masashi
authors.initials: M
authors.lastname: Matsushima
authors.forename: Minoru
authors.initials: M
authors.lastname: Horinaga
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Fukuyama
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Yanaihara
authors.forename: Eiji
authors.initials: E
authors.lastname: Kikuchi
authors.forename: Makoto
authors.initials: M
authors.lastname: Kawachi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Iida
authors.forename: Yoko
authors.initials: Y
authors.lastname: Nakahira
authors.forename: Mototsugu
authors.initials: M
authors.lastname: Oya
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Asakura